The resignation of FDA Commissioner Marty Makary in mid-May 2026 and President Trump’s immediate appointment of Kyle Diamantas as acting commissioner have positioned Diamantas as the clear frontrunner in trader consensus for the permanent nomination. Diamantas’s prior service as deputy commissioner for food and his direct endorsement by the president as a “very talented person” provide an institutional advantage that other candidates lack. Stephen Hahn, Brett Giroir, Sara Brenner, and Grace Graham remain distant alternatives based on their earlier roles in prior administrations or agency positions, yet none have received comparable recent elevation or public backing. The low probability assigned to no announcement by year-end reflects expectations that the White House will move forward with a formal nomination and Senate confirmation process in the coming months.
Polymarketデータを参照したAI生成の実験的な要約。これは取引アドバイスではなく、このマーケットの解決方法には一切関係ありません。 · 更新日Kyle Diamantas 43%
Stephen Hahn 7%
Sara Brenner 3.3%
Brett Giroir 3.2%
新規
新規
2026/12/31
Kyle Diamantas
50%
Stephen Hahn
7%
Brett Giroir
3%
Grace Graham
3%
Sara Brenner
3%
No announcement by December 31
1%
Kyle Diamantas 43%
Stephen Hahn 7%
Sara Brenner 3.3%
Brett Giroir 3.2%
新規
新規
2026/12/31
Kyle Diamantas
$1,298 Vol.
50%
Stephen Hahn
$975 Vol.
7%
Brett Giroir
$1,510 Vol.
3%
Grace Graham
$1,842 Vol.
3%
Sara Brenner
$848 Vol.
3%
No announcement by December 31
$425 Vol.
1%
This market will resolve according to the first individual Donald Trump announces as his pick to be United States Food and Drug Administration (FDA) Commissioner.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.The resignation of FDA Commissioner Marty Makary in mid-May 2026 and President Trump’s immediate appointment of Kyle Diamantas as acting commissioner have positioned Diamantas as the clear frontrunner in trader consensus for the permanent nomination. Diamantas’s prior service as deputy commissioner for food and his direct endorsement by the president as a “very talented person” provide an institutional advantage that other candidates lack. Stephen Hahn, Brett Giroir, Sara Brenner, and Grace Graham remain distant alternatives based on their earlier roles in prior administrations or agency positions, yet none have received comparable recent elevation or public backing. The low probability assigned to no announcement by year-end reflects expectations that the White House will move forward with a formal nomination and Senate confirmation process in the coming months.
This market will resolve according to the first individual Donald Trump announces as his pick to be United States Food and Drug Administration (FDA) Commissioner.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.
マーケット開始日： May 12, 2026, 7:59 PM ET
音量
$6,898終了日
2026/12/31マーケット開始日
May 12, 2026, 7:59 PM ETResolver
0x69c47De9D...This market will resolve according to the first individual Donald Trump announces as his pick to be United States Food and Drug Administration (FDA) Commissioner.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.The resignation of FDA Commissioner Marty Makary in mid-May 2026 and President Trump’s immediate appointment of Kyle Diamantas as acting commissioner have positioned Diamantas as the clear frontrunner in trader consensus for the permanent nomination. Diamantas’s prior service as deputy commissioner for food and his direct endorsement by the president as a “very talented person” provide an institutional advantage that other candidates lack. Stephen Hahn, Brett Giroir, Sara Brenner, and Grace Graham remain distant alternatives based on their earlier roles in prior administrations or agency positions, yet none have received comparable recent elevation or public backing. The low probability assigned to no announcement by year-end reflects expectations that the White House will move forward with a formal nomination and Senate confirmation process in the coming months.
This market will resolve according to the first individual Donald Trump announces as his pick to be United States Food and Drug Administration (FDA) Commissioner.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.
音量
$6,898終了日
2026/12/31マーケット開始日
May 12, 2026, 7:59 PM ETResolver
0x69c47De9D...The resignation of FDA Commissioner Marty Makary in mid-May 2026 and President Trump’s immediate appointment of Kyle Diamantas as acting commissioner have positioned Diamantas as the clear frontrunner in trader consensus for the permanent nomination. Diamantas’s prior service as deputy commissioner for food and his direct endorsement by the president as a “very talented person” provide an institutional advantage that other candidates lack. Stephen Hahn, Brett Giroir, Sara Brenner, and Grace Graham remain distant alternatives based on their earlier roles in prior administrations or agency positions, yet none have received comparable recent elevation or public backing. The low probability assigned to no announcement by year-end reflects expectations that the White House will move forward with a formal nomination and Senate confirmation process in the coming months.
Polymarketデータを参照したAI生成の実験的な要約。これは取引アドバイスではなく、このマーケットの解決方法には一切関係ありません。 · 更新日
外部リンクに注意してください。
外部リンクに注意してください。
よくある質問